Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov 15;128(22):4027-4028.
doi: 10.1002/cncr.34460. Epub 2022 Sep 28.

von Hippel-Lindau disease integrated care pathway: Centralizing, expanding specialists' theatre, and measuring improvement

Mario Gardi  1 , Umberto Basso  2 , Alfonso Massimiliano Ferrara  3 , Stefania Zovato  3 , Alberto Feletti  4 , Sara Watutantrige-Fernando  3 , Fabrizio Dal Moro  1 , Giuseppe Opocher  3 ; VHL-Padova Network
Affiliations
Free article
Comment

von Hippel-Lindau disease integrated care pathway: Centralizing, expanding specialists' theatre, and measuring improvement

Mario Gardi et al. Cancer. .
Free article
No abstract available

PubMed Disclaimer

Comment in

Comment on

  • Multidisciplinary integrated care pathway for von Hippel-Lindau disease.
    Wolters WPG, Dreijerink KMA, Giles RH, van der Horst-Schrivers ANA, van Nesselrooij B, Zandee WT, Timmers HJLM, Seute T, de Herder WW, Verrijn Stuart AA, Kilic E, Brinkman WM, Zondervan PJ, Vandertop WP, Daniels AB, Wolbers T, Links TP, van Leeuwaarde RS. Wolters WPG, et al. Cancer. 2022 Aug 1;128(15):2871-2879. doi: 10.1002/cncr.34265. Epub 2022 May 17. Cancer. 2022. PMID: 35579632 Free PMC article.

References

REFERENCES

    1. Wolters WPG, Dreijerink KMA, Giles RH, et al. Multidisciplinary integrated care pathway for von Hippel-Lindau disease. Cancer. 2022;128(15):2871-2879. doi:10.1002/cncr.34265
    1. Feletti A, Anglani M, Scarpa B, et al. Von Hippel-Lindau disease: an evaluation of natural history and functional disability. Neuro Oncol. 2016;18(7):1011-1020. doi:10.1093/neuonc/nov313
    1. VHL Alliance Tertiary Care. VHL Alliance; 2022. Accessed June 24, 2022. https://www.vhl.org/clinicians/tertiary-care/
    1. Roma A, Maruzzo M, Basso U, et al. First-line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. Fam Cancer. 2015;14(2):309-316. doi:10.1007/s10689-014-9771-y
    1. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R, MK-6482-004 Investigators.; MK-6482-004 Investigators. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med 2021 25;385(22):2036-2046. doi:10.1056/NEJMoa2103425

MeSH terms

LinkOut - more resources